Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
- Author
- CHUA, S1 ; SMITH, I. E1 ; WARDLEY, A9 ; MUGHAL, T10 ; VERRILL, M11 ; DUBOIS, D12 ; BLISS, J. M2 ; A'HERN, R. P1 ; COOMBES, G. A2 ; HICKISH, T. F3 ; ROBINSON, A. C4 ; LAING, R. W5 ; O'BRIEN, M. E. R6 ; EBBS, S. R7 ; HONG, A8
[1] Royal Marsden Hospital, London and Sutton, United Kingdom
[2] Institute of Cancer Research, United Kingdom
[3] Royal Bournemouth and Poole Hospitals, United Kingdom
[4] Southend Hospital, United Kingdom
[5] St Luke's Cancer Centre, Guildford, Surrey, United Kingdom
[6] Kent Oncology Centre, United Kingdom
[7] Mayday University Hospital, Croydon, United Kingdom
[8] Royal Devon and Exeter Hospital, United Kingdom
[9] Christie Hospital, Manchester, United Kingdom
[10] Royal Lancaster Infirmary, United Kingdom
[11] Northern Centre for Cancer Treatment, United Kingdom
[12] Portsmouth Oncology Centre, Portsmouth, United Kingdom
TOPIC Trial Group, United Kingdom - Source
Annals of oncology. 2005, Vol 16, Num 9, pp 1435-1441, 7 p ; ref : 28 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- breast cancer chemotherapy epirubicin neoadjuvant phase III vinorelbine
- Keyword (fr)
- Analyse Anticancéreux Chimiothérapie Cyclophosphamide Doxorubicine Epirubicine Essai clinique phase III Essai clinique Etude comparative Homme Norme Toxicité Traitement néoadjuvant Vinorelbine Cancer sein Agent alkylant Alcaloïde Anthracyclines Antimitotique DNA topoisomerase (ATP-hydrolysing) Enzyme Glande mammaire pathologie Inhibiteur enzyme Isomerases Moutarde à l'azote Oxazaphosphinane dérivé Tumeur maligne
- Keyword (en)
- Analysis Antineoplastic agent Chemotherapy Cyclophosphamide Doxorubicin Epirubicin Phase III trial Clinical trial Comparative study Human Standards Toxicity Neoadjuvant treatment Vinorelbine Breast cancer Alkylating agent Alkaloid Anthracyclins Antimitotic DNA topoisomerase (ATP-hydrolysing) Enzyme Mammary gland diseases Enzyme inhibitor Isomerases Nitrogen mustard Oxazaphosphinane derivatives Malignant tumor
- Keyword (es)
- Análisis Anticanceroso Quimioterapia Ciclofosfamida Doxorubicina Epirubicina Ensayo clínico fase III Ensayo clínico Estudio comparativo Hombre Norma Toxicidad Neocoadyuvante tratamiento Vinorelbina Cáncer pecho Agente alquilante Alcaloide Antraciclinas Antimitótico DNA topoisomerase (ATP-hydrolysing) Enzima Glándula mamaria patología Inhibidor enzima Isomerases Mostaza al nitrógeno Oxazafosfinano derivado Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17097485
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdi276 
https://dx.doi.org/10.1093/annonc/mdi276
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdi276\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1435\";s:8:\"\u0000*\u0000epage\";s:4:\"1441\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHUA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"SMITH, I. E\";i:1;s:10:\"WARDLEY, A\";i:2;s:9:\"MUGHAL, T\";i:3;s:10:\"VERRILL, M\";i:4;s:9:\"DUBOIS, D\";i:5;s:11:\"BLISS, J. M\";i:6;s:12:\"A'HERN, R. P\";i:7;s:13:\"COOMBES, G. A\";i:8;s:13:\"HICKISH, T. F\";i:9;s:14:\"ROBINSON, A. C\";i:10;s:11:\"LAING, R. W\";i:11;s:16:\"O'BRIEN, M. E. R\";i:12;s:10:\"EBBS, S. R\";i:13;s:7:\"HONG, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdi276\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1435\";s:8:\"\u0000*\u0000epage\";s:4:\"1441\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHUA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"SMITH, I. E\";i:1;s:10:\"WARDLEY, A\";i:2;s:9:\"MUGHAL, T\";i:3;s:10:\"VERRILL, M\";i:4;s:9:\"DUBOIS, D\";i:5;s:11:\"BLISS, J. M\";i:6;s:12:\"A'HERN, R. P\";i:7;s:13:\"COOMBES, G. A\";i:8;s:13:\"HICKISH, T. F\";i:9;s:14:\"ROBINSON, A. C\";i:10;s:11:\"LAING, R. W\";i:11;s:16:\"O'BRIEN, M. E. R\";i:12;s:10:\"EBBS, S. R\";i:13;s:7:\"HONG, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdi276\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdi276\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1435\";s:8:\"\u0000*\u0000epage\";s:4:\"1441\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHUA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"SMITH, I. E\";i:1;s:10:\"WARDLEY, A\";i:2;s:9:\"MUGHAL, T\";i:3;s:10:\"VERRILL, M\";i:4;s:9:\"DUBOIS, D\";i:5;s:11:\"BLISS, J. M\";i:6;s:12:\"A'HERN, R. P\";i:7;s:13:\"COOMBES, G. A\";i:8;s:13:\"HICKISH, T. F\";i:9;s:14:\"ROBINSON, A. C\";i:10;s:11:\"LAING, R. W\";i:11;s:16:\"O'BRIEN, M. E. R\";i:12;s:10:\"EBBS, S. R\";i:13;s:7:\"HONG, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdi276\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1435\";s:8:\"\u0000*\u0000epage\";s:4:\"1441\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHUA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"SMITH, I. E\";i:1;s:10:\"WARDLEY, A\";i:2;s:9:\"MUGHAL, T\";i:3;s:10:\"VERRILL, M\";i:4;s:9:\"DUBOIS, D\";i:5;s:11:\"BLISS, J. M\";i:6;s:12:\"A'HERN, R. P\";i:7;s:13:\"COOMBES, G. A\";i:8;s:13:\"HICKISH, T. F\";i:9;s:14:\"ROBINSON, A. C\";i:10;s:11:\"LAING, R. W\";i:11;s:16:\"O'BRIEN, M. E. R\";i:12;s:10:\"EBBS, S. R\";i:13;s:7:\"HONG, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdi276\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1435\";s:8:\"\u0000*\u0000epage\";s:4:\"1441\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHUA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"SMITH, I. E\";i:1;s:10:\"WARDLEY, A\";i:2;s:9:\"MUGHAL, T\";i:3;s:10:\"VERRILL, M\";i:4;s:9:\"DUBOIS, D\";i:5;s:11:\"BLISS, J. M\";i:6;s:12:\"A'HERN, R. P\";i:7;s:13:\"COOMBES, G. A\";i:8;s:13:\"HICKISH, T. F\";i:9;s:14:\"ROBINSON, A. C\";i:10;s:11:\"LAING, R. W\";i:11;s:16:\"O'BRIEN, M. E. R\";i:12;s:10:\"EBBS, S. R\";i:13;s:7:\"HONG, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:196:\"Neoadjuvant vinorelbine\/epirubicin (VE) versus standard adriamycin\/cyclophosphamide (AC) in operable breast cancer : analysis of response and tolerability in a randomised phase III trial (TOPIC 2)\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
